HCW Biologics (NASDAQ: HCWB) announced a pricing of a follow-on at-the-market offering of 2,477,292 units at $0.6055 per unit, aiming to raise approximately $1.5 million before fees. The company also plans to seek shareholder approval to reduce the exercise price of up to 3,020,410 existing warrants to $0.6055 per share. Proceeds are intended for funding preclinical and clinical development, specifically for HCW9302, and for general corporate purposes.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
HCW Biologics lines up $1.5M, cuts warrant price to $0.6055
HCW Biologics (NASDAQ: HCWB) announced a pricing of a follow-on at-the-market offering of 2,477,292 units at $0.6055 per unit, aiming to raise approximately $1.5 million before fees. The company also plans to seek shareholder approval to reduce the exercise price of up to 3,020,410 existing warrants to $0.6055 per share. Proceeds are intended for funding preclinical and clinical development, specifically for HCW9302, and for general corporate purposes.